Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 4/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.53 |
| ▸ | USP2 | O75604 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.53 |
| ▸ | HPGD | P15428 | 4/20 | 0.52 |
| ▸ | LMNA | P02545 | 3/20 | 0.52 |
| ▸ | HTT | P42858 | 2/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | ESR1 | P03372 | 1/20 | 0.52 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.52 |
| ▸ | PKM | P14618 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | PGR | P06401 | 1/20 | 0.51 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.51 |
| ▸ | PDE4A | P27815 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1456378 | 0.87 | HPGD (0.68) | CYP3A4MAPK1USP2SMN1; SMN2CYP2D6 | |
| SCHEMBL19018122 | 0.82 | MAPT (0.68) | MAPK1HPGDLMNAHTTMAPT | |
| SCHEMBL1817437 | 0.82 | MAPT (0.68) | MAPK1HPGDLMNAHTTMAPT | |
| Iriflophenone SCHEMBL9148205 | 0.81 | FASN (0.67) | CYP3A4MAPK1USP2SMN1; SMN2CYP2D6 | |
| SCHEMBL38661406 | 0.81 | CYP2D6 (0.54) | CYP3A4MAPK1SMN1; SMN2CYP2D6CYP2C19 | |
| SCHEMBL6171166 | 0.80 | HPGD (0.79) | CYP3A4MAPK1USP2SMN1; SMN2CYP2D6 | |
| SCHEMBL7484630 | 0.80 | LMNA (0.56) | MAPK1SMN1; SMN2CYP2C19HPGDLMNA | |
| SCHEMBL15317154 | 0.79 | LMNA (0.50) | CYP3A4MAPK1SMN1; SMN2HPGDLMNA | |
| SCHEMBL7511557 | 0.79 | MAPT (0.63) | CYP3A4MAPK1USP2SMN1; SMN2CYP2D6 | |
| SCHEMBL8132899 | 0.79 | MKNK2 (0.52) | CYP3A4MAPK1USP2SMN1; SMN2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120070515-A1 | Composition Comprising the Extract of Anemarrhena Asphodeloides Bunge or the Compounds Isolated from the Same for Preventing and Treating Lipid Metabolism Disorder | EWHA UNIVERSITY- INDUSTRY COLLABORATION FOUNDATION (KR) | 2012-03-22 | — | — | US | claimed |
| WO-2010120029-A1 | COMPOSITION COMPRISING THE EXTRACT OF ANEMARRHENA ASPHODELOIDES BUNGE OR THE COMPOUNDS ISOLATED FROM THE SAME FOR PREVENTING AND TREATING LIPID METABOLISM DISORDER | EWHA UNIVERSITY - INDUSTRY COLLABORATION FOUNDATION (KR) | 2010-10-21 | — | — | WO | claimed |
| US-20050080260-A1 | Preparation of prodrugs for selective drug delivery | LUMINIDE | 2005-04-14 | — | — | US | claimed |
| CN-120944240-A | Anti-aging push-pull sleeve material for vehicle and anti-aging push-pull sleeve for vehicle | 江阴市腾飞塑料制品有限公司 | 2025-11-14 | — | — | CN | disclosed |
| US-20250213593-A1 | Use of Derivatives based on Sarsasapogenin Structure and Pharmaceutical Compositions thereof | BEIJING PHYTOVENT PHARMACEUTICAL TECHNOLOGY CO., LTD. (CN) | 2025-07-03 | — | — | US | disclosed |
| EP-4477225-A1 | USE OF SARSASAPOGENIN STRUCTURE-BASED DERIVATIVE AND PHARMACEUTICAL COMPOSITION THEREOF | Beijing Phytovent Pharmaceutical Technology Co., Ltd. (CN) | 2024-12-18 | — | — | EP | disclosed |
| EP-3564253-B1 | ANTIDEPRESSANT COMPOUND AND PREPARATION METHOD AND APPLICATION THEREOF | SHANGHAI INST MATERIA MEDICA CAS (CN) | 2024-10-30 | — | — | EP | disclosed |
| WO-2023155757-A1 | USE OF SARSASAPOGENIN STRUCTURE-BASED DERIVATIVE AND PHARMACEUTICAL COMPOSITION THEREOF | 北京清博汇能医药科技有限公司 | 2023-08-24 | — | — | WO | disclosed |
| CN-116621912-A | Derivatives based on sarsasapogenin structure and use of pharmaceutical compositions thereof | 北京清博汇能医药科技有限公司 | 2023-08-22 | — | — | CN | disclosed |
| CN-109988218-B | Sarsasapogenin derivative and preparation method and application thereof | 中国科学院上海药物研究所 | 2022-11-25 | — | — | CN | disclosed |
| CN-110121502-B | Anti-depression compound and preparation method and application thereof | 中国科学院上海药物研究所 | 2022-09-23 | — | — | CN | disclosed |
| WO-2010120029-A1 | COMPOSITION COMPRISING THE EXTRACT OF ANEMARRHENA ASPHODELOIDES BUNGE OR THE COMPOUNDS ISOLATED FROM THE SAME FOR PREVENTING AND TREATING LIPID METABOLISM DISORDER | EWHA UNIVERSITY - INDUSTRY COLLABORATION FOUNDATION (KR) | 2010-10-21 | — | — | WO | disclosed |
| US-20050080260-A1 | Preparation of prodrugs for selective drug delivery | LUMINIDE | 2005-04-14 | — | — | US | disclosed |
| US-6555663-B1 | Pharmaceuticals which are activated intracellularly by reaction with cellular electron carriers or free radicals to cause release of a free and active drug molecule | MILLS RANDELL LEE (US) | 2003-04-29 | — | — | US | disclosed |
| EP-0414730-B1 | Chemical Compounds and pharmaceutical compositions capable of releasing a drug | MILLS RANDELL L (US) | 1999-12-15 | — | — | EP | disclosed |
| US-5773592-A | COMPRISES A CHEMILUMINESCENT MOIETY, A PHOTOCHROMIC MOIETY AND A BIOLOGICALLY ACTIVE AGENT CAPABLE OF BEING RELEASED | MILLS RANDELL LEE (US) | 1998-06-30 | — | — | US | disclosed |
| US-5428163-A | Luminides; chemiluminescence; redox system, releasing free drug | MILLS RANDELL L (US) | 1995-06-27 | — | — | US | disclosed |
| EP-0414730-A4 | LUMINIDE AND MACROLUMINIDE CLASS OF PHARMACEUTICALS | — | 1993-06-16 | — | — | EP | disclosed |
| EP-0414730-A1 | LUMINIDE AND MACROLUMINIDE CLASS OF PHARMACEUTICALS | Mills, Randell L. (US) | 1991-03-06 | — | — | EP | disclosed |
| WO-1989009833-A1 | LUMINIDE AND MACROLUMINIDE CLASS OF PHARMACEUTICALS | MILLS RANDELL L (US) | 1989-10-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050080260-A1 | Preparation of prodrugs for selective drug delivery | APEH, PAH, ALAD | CYP3A4 84/4885MAPK1 3847/4885USP2 2734/4885 |
| US-20250213593-A1 | Use of Derivatives based on Sarsasapogenin Structure and Pharmaceutical Compositions thereof | MAVS, NLN, TFAM | CYP3A4 1166/4885MAPK1 3031/4885USP2 3601/4885 |
| US-20120070515-A1 | Composition Comprising the Extract of Anemarrhena Asphodeloides Bunge or the Compounds Isolated from the Same for Preventing and Treating Lipid Metabolism Disorder | FABP4, ACACB, LIPC | CYP3A4 1261/4885MAPK1 2956/4885USP2 1603/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.